A meta-analysis by Liu et al. reported that NSCLC (non-small lung cancers) with ALK (anaplastic lymphoma kinase) or ROS1 (ROS proto-oncogene 1 receptor tyrosine kinase) were more likely to develop thrombosis than patients without these molecular aberrations. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.